Pharmacogenetics
Pharmacogenetics can improve identification of high-risk ALL patients
Published in Hematology Week, August 2nd, 2004
"Present-day pediatric cooperative group acute lymphoblastic leukemia (ALL) protocols cure approximately 80% of patients, a result achieved largely through the use of risk-stratified therapies that employ multiple chemotherapy agents.
"These risk-based therapies utilize host and leukemia traits to select the most appropriate therapy. However, these risk-stratified approaches predict therapy response imperfectly and an important fraction of patients experience relapse or therapy-related toxicity," scientists in the United States report.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
Source: Hematology Week (2004-08-02)
More Articles from Hematology Week
- Chronic Lymphocytic Leukemia
Alemtuzumab effective therapy for CLL with p53 mutations and deletions - Graft Versus Host Disease
DC stimulation of donor CD8+ T cells may be useful for prevention of GVHD - Stem Cell Transplantation
Primary systemic amyloidosis patients have increased survival following PBSCT - Tumor Suppression
p300 and CBP are suppressors of hematological tumor formation - Acute Lymphoblastic Leukemia
Novel FLT3 inhibitors may be considered to treat hyperdiploid or relapsed ALL - Acute Myeloid Leukemia
FLT3 mutations in AML adversely associate with CR with intensive chemotherapy - More from this issue of Hematology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
